Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome

Phase 3 Completed 125 enrolled Seaside Therapeutics, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To explore the efficacy, safety and tolerability of STX209 (arbaclofen) administered for the treatment of social withdrawal in adolescents and adults with fragile X syndrome (FXS)

Timeline

Start: 2011-05
Primary completion: 2012-12
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Arbaclofen	Small molecule	—	—

Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome

Summary

Timeline

Drugs

Indications